Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Qiagen ( (QGEN) ) is now available.
QIAGEN has reported that the Dutch financial markets regulator AFM notified the company of a substantial shareholding disclosure by Goldman Sachs Group Inc. as of January 27, 2026. According to the AFM register, various Goldman Sachs entities collectively hold a 3.26% capital and voting interest in QIAGEN through a mix of directly held ordinary shares, convertible bonds, swaps, warrants and options, largely on an indirect and potential basis. The announcement highlights a notable institutional position in QIAGEN’s stock structure, indicating continued interest from major global financial institutions in the company’s equity, though QIAGEN stresses that it is not responsible for the accuracy of the AFM data.
The most recent analyst rating on (QGEN) stock is a Buy with a $60.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
QIAGEN N.V., based in Venlo, Netherlands, is listed on multiple European exchanges as well as the NYSE and focuses on life-science and molecular diagnostics products and services for research and clinical markets worldwide.
Average Trading Volume: 1,841,283
Technical Sentiment Signal: Strong Buy
Current Market Cap: $11.1B
See more data about QGEN stock on TipRanks’ Stock Analysis page.